We chose to evaluate a dose (100 mg/kg/day) that had previously been shown to maximally inhibit both COX-1 and COX-2 [147] and had been shown to improve vascular dysfunction, cardiac hypertrophy, and oxidative stress in SHRSP and angiotensin II-induced hypertensive mice [20]. The gene discussed is AGT; the disease is cardiac hypertrophy.